Overview
- Justice Department action moved FDA‑approved cannabis drugs and marijuana sold under state medical licenses to Schedule III and created an expedited DEA registration path for those businesses.
- The policy is narrowly scoped to medical programs and does not legalize recreational cannabis under federal law.
- Schedule III status removes the IRS limit known as Section 280E for qualifying firms, which should allow normal business deductions and improve cash flow as Treasury considers possible retroactive relief.
- Banks may become more willing to offer loans and accounts to registered medical operators, yet no statutory safe harbor exists and existing FinCEN reporting and customer‑vetting rules would still apply.
- State‑licensed applicants must show strict controls for storage, dispensing, inventory and recordkeeping, with a DEA hearing on broader rescheduling set for June 29.